The FDA have already approved celecoxib for increased degradation of CTNNB1 gene mutations (β-catenin oncoprotein), frequently observed in colon cancer cells, and for reducing the number of colorectal polyps in patients with familial adenomatous polyposis [36,37]. This evidence concerns the gene CTNNB1 and colonic neoplasm.